For the quarter ending 2026-03-31, ADTX had -$2,929,747 decrease in cash & cash equivalents over the period. -$4,589,091 in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Stock-based compensation | - | 0 | 0 | 473,311 |
| Net loss | -16,189,200 | -5,231,251 | -24,207,669 | -13,348,123 |
| Depreciation expense | 47,882 | 66,807 | 66,966 | 135,498 |
| Stock-based compensation from asset purchase | - | 0 | 0 | 10,000 |
| Amortization of intangible assets | 834 | 833 | 833 | 1,667 |
| Amortization of debt discount - note payable | 24,687 | 60,000 | 234,167 | 1,412,530 |
| Amortization of debt discount - note receivable | - | 12,680 | 108,112 | 99,897 |
| Change in fair value of derivative liability | 11,800,798 | -228 | -162 | -14,125 |
| Loss on note exchange agreement | - | 0 | 0 | 0 |
| Redemptions of a-1 preferred stock | - | - | 0 | 308,000 |
| Impairment of evofem f-1 preferred stock | - | 764,290 | 23,001,919 | - |
| Change in fair value of evofem warrants | -25,004 | -358,413 | -2,511,781 | 63,211 |
| Redemptions of c-1 preferred stock | - | - | - | 7,027,065 |
| Deposits | - | -183,112 | 28,752 | 128,274 |
| Credit loss on evofem notes | - | - | 350,000 | - |
| Bargain purchase gain from purchase of evofem convertible notes | - | -328,071 | - | - |
| Impairment of fixed assets | 32,275 | 412,005 | - | - |
| Cash from subscription receivable | - | 149,027 | -149,027 | 1,108,751 |
| Modification of warrants for debt issuance costs | - | 0 | 0 | - |
| Accounts receivable | 11,974 | -39,182 | -561 | -3,692 |
| New principal from extension of notes, net of debt discount | - | 0 | 0 | 0 |
| Prepaid expenses | -294,310 | 554,746 | 0 | 59,237 |
| Disposal of fixed assets | - | 0 | - | - |
| Settlement liability | - | 0 | - | 0 |
| Other assets | - | - | 75,229 | - |
| Inventory | -9,289 | -798 | -1,045 | -3,628 |
| Settlement liability | - | - | 0 | - |
| Accounts payable and accrued expenses | -562,609 | -4,012,540 | 931,660 | -2,552,013 |
| Net cash used in operating activities | -4,578,712 | -9,245,673 | -2,344,554 | -14,098,132 |
| Purchases of fixed assets | 10,379 | 13,743 | - | - |
| Investment in notes receivable and warrants | - | - | 2,425,000 | - |
| Investment in convertible notes receivable and warrants | - | 0 | - | 2,425,000 |
| Investment in evofem f-1 preferred stock | - | 0 | 0 | 0 |
| Repayments of note payable, related party | - | -185,000 | 0 | -608,000 |
| Net cash used in investing activities | -10,379 | -13,743 | 0 | -2,425,000 |
| Proceeds from notes payable, related party | - | 0 | 185,000 | 493,000 |
| Proceeds from notes and convertible notes payable, net of offering costs | 2,855,000 | -483,001 | 170,000 | 1,504,019 |
| Repayments of note payable | 1,428,921 | 2,421,248 | 265,874 | 3,926,760 |
| Common stock, preferred stock, and warrants issued for cash, net of issuance costs | 603,261 | 16,789,941 | 2,560,449 | 24,777,835 |
| Redemptions of a-1 preferred stock | 369,996 | 308,000 | - | - |
| Redemptions of c-1 preferred stock | - | 1,554,745 | 7,343,697 | - |
| Proceeds from exercises of warrants | - | 0 | 0 | - |
| Redemptions of d-1 preferred stock | - | 0 | - | - |
| Net increase in cash | - | 2,874,920 | - | - |
| Net cash provided by financing activities | 1,659,344 | 12,294,974 | 2,183,916 | 16,013,780 |
| Net increase (decrease) in cash | - | - | -669,990 | - |
| Net decrease in cash | -2,929,747 | 2,874,920 | - | -509,352 |
| Cash at beginning of period | 3,198,599 | 163,041 | 833,031 | - |
| Cash at end of period | 268,852 | 3,198,599 | 163,041 | - |
Aditxt, Inc. (ADTX)
Aditxt, Inc. (ADTX)